Patient-Derived Gastric Cancer Assembloids Reveal Microenvir
2026-06-02
This study introduces a patient-derived gastric cancer assembloid system that integrates matched tumor organoids with stromal cell subpopulations, closely mimicking the complexity of primary tumors. The model demonstrates that stromal components significantly influence gene expression and drug sensitivity, offering a physiologically relevant platform for personalized therapy discovery and resistance mechanism studies.
Redox Precision: NADH as a Strategic Lever in Translational
2026-06-02
Explore how reduced nicotinamide adenine dinucleotide (NADH) is redefining translational research. This thought-leadership article synthesizes mechanistic insights, experimental strategies, and competitive positioning to help researchers harness NADH for disease modeling, mitochondrial electron transport chain research, and next-generation therapies. Built on peer-reviewed evidence and advanced product standards like APExBIO’s NADH (CAS 58-68-4), this guide elevates the conversation from routine protocols to strategic redox innovation.
Eicosapentaenoic Acid: Omega-3 Fatty Acid Protocols & Insigh
2026-06-01
Eicosapentaenoic Acid (EPA) stands out as an advanced omega-3 fatty acid tool for cardiovascular and immunomodulatory research. This article delivers hands-on protocol guidelines, troubleshooting, and evidence-based innovations to help bench scientists achieve reproducible, high-impact results with APExBIO's EPA.
Influenza Hemagglutinin (HA) Peptide: Elevating Epitope Tag
2026-06-01
The Influenza Hemagglutinin (HA) Peptide stands out as a gold-standard epitope tag for protein detection and purification, offering unmatched solubility and competitive elution performance. APExBIO’s A6004 product empowers advanced immunoprecipitation, high-sensitivity interaction mapping, and robust troubleshooting capabilities for modern molecular biology labs.
BKT140 (BL-8040): Transforming CXCR4 Inhibition in Tumor Mic
2026-05-31
Explore how BKT140 (BL-8040) is redefining CXCR4-targeted oncology by enabling advanced interrogation of tumor microenvironment dynamics, stem cell mobilization, and apoptosis in cancer cells. This article delivers unique protocol insights and bridges mechanistic understanding with translational research applications.
CXCR4-Targeted Theranostics in Lymphoma: Imaging and Therapy
2026-05-30
This review details recent advances in CXCR4-targeted imaging and therapeutic strategies for lymphoma, emphasizing the biological rationale for CXCR4 as a diagnostic and therapeutic target. Integrating molecular imaging agents and targeted antagonists, the study highlights how these approaches can personalize and improve lymphoma management.
Phosphatase Inhibitor Cocktail 1: Precision Tools for Phosph
2026-05-29
Explore how Phosphatase Inhibitor Cocktail 1 (100X in DMSO) enables uncompromised protein phosphorylation preservation for advanced phosphoproteomic analyses. This in-depth article uniquely integrates mechanistic insight, translational impact, and protocol optimization for researchers targeting complex signaling pathways.
AT-406 (SM-406) and the Next Wave of Apoptosis Pathway Modul
2026-05-29
This article provides translational researchers with a strategic, mechanistic, and forward-looking perspective on how AT-406 (SM-406) enables precise modulation of apoptosis pathways in cancer cells. By integrating the latest structural insights into death receptor signaling, evaluating experimental validation, and contextualizing competitive differentiation, we outline how AT-406 is advancing the field beyond standard inhibitor paradigms and shaping the future of translational oncology.
Moxifloxacin: Fluoroquinolone Antibiotic for Advanced Toxici
2026-05-28
Moxifloxacin, a broad-spectrum fluoroquinolone antibiotic, is redefining in vitro and in vivo research through its unique mechanistic action on DNA gyrase and dose-dependent effects on cell viability and metabolism. This article delivers actionable workflows, protocol optimization, and practical troubleshooting, empowering researchers to harness Moxifloxacin for high-impact studies in antibiotic toxicity, cellular proliferation, and metabolic response.
WY-14643 (Pirinixic Acid): PPARα Agonist in Tumor Microenvir
2026-05-28
Explore the unique role of WY-14643 (Pirinixic Acid) as a selective PPARα agonist in modulating the tumor microenvironment, with a focus on recent mechanistic insights and advanced applications in metabolic and oncology research. This cornerstone article delivers distinct, evidence-based guidance beyond standard metabolic disorder studies.
Strategic Use of Z-VAD-FMK to Decipher Apoptosis and PANopto
2026-05-27
This thought-leadership article empowers translational researchers to navigate the evolving landscape of programmed cell death, spotlighting Z-VAD-FMK as a crucial mechanistic probe. We dissect the interplay of apoptosis and lytic cell death, integrate new insights from recent PANoptosis research, and provide actionable protocol guidance, bridging foundational biology with advanced translational strategy.
Tumor-Targeted PAD4 Inhibitors Disrupt NETs to Suppress Meta
2026-05-27
This study introduces phenylboronic acid-modified PAD4 inhibitors that selectively target tumor cells and neutrophils, effectively disrupting the PAD4-H3cit-NETs pathway to inhibit tumor growth and metastasis in vivo. The findings highlight a new approach for reducing cancer progression by modulating neutrophil extracellular trap formation.
scaRNA1 Disruption Alters U2 snRNA Modification and Splicing
2026-05-26
Gardner-Kay et al. used CRISPR-Cas9 to disrupt scaRNA1 in HEK293T cells, revealing its essential role in directing U2 snRNA pseudouridylation at U89 and maintaining normal mRNA splicing patterns. Their findings clarify how noncoding RNA-guided RNA modifications can broadly influence transcriptomic regulation, with implications for understanding developmental disorders.
Berberrubine Inhibits Thrombosis via Vitamin K Cycle Modulat
2026-05-26
Wang et al. employed integrated metabolomics and molecular docking to reveal that berberrubine, a primary metabolite of berberine, inhibits thrombosis in mice by regulating the vitamin K catalytic cycle. This mechanistic insight highlights berberrubine's potential as a safer antithrombotic agent that does not increase bleeding risk, with implications for future drug development.
LNP-NamiRNA Dual Pathways Suppress Pancreatic Cancer Progres
2026-05-26
Yu et al. (2025) demonstrate that LNP-delivered mir-200c, acting as a nuclear activating miRNA (NamiRNA), suppresses pancreatic cancer proliferation and migration via dual regulatory mechanisms: transcriptional activation of PTPN6 and post-transcriptional repression of CDH17. These findings position LNP-based NamiRNA delivery as a promising therapeutic avenue, highlighting new regulatory complexity in miRNA biology.
466 records 17/32 page Previous Next First page 上5页 1617181920 下5页 Last page